HK1158563A1 - Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions thereof, and methods of use - Google Patents
Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions thereof, and methods of useInfo
- Publication number
- HK1158563A1 HK1158563A1 HK11113251.4A HK11113251A HK1158563A1 HK 1158563 A1 HK1158563 A1 HK 1158563A1 HK 11113251 A HK11113251 A HK 11113251A HK 1158563 A1 HK1158563 A1 HK 1158563A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- prodrugs
- methods
- pharmaceutical compositions
- methyl hydrogen
- hydrogen fumarate
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C235/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C235/08—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C235/10—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by nitrogen atoms not being part of nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C235/12—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
- C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
- C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/62—Compounds containing any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylcarbamates
- C07C271/64—Y being a hydrogen or a carbon atom, e.g. benzoylcarbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/46—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylureas
- C07C275/48—Y being a hydrogen or a carbon atom
- C07C275/50—Y being a hydrogen or an acyclic carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/52—Esters of acyclic unsaturated carboxylic acids having the esterified carboxyl group bound to an acyclic carbon atom
- C07C69/593—Dicarboxylic acid esters having only one carbon-to-carbon double bond
- C07C69/60—Maleic acid esters; Fumaric acid esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/74—Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring
- C07C69/75—Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring of acids with a six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
- C07C69/78—Benzoic acid esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/96—Esters of carbonic or haloformic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/18—Oxygen atoms
- C07D263/20—Oxygen atoms attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Hydrogenated Pyridines (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pyrrole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9016308P | 2008-08-19 | 2008-08-19 | |
PCT/US2009/054349 WO2010022177A2 (en) | 2008-08-19 | 2009-08-19 | Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions thereof, and methods of use |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1158563A1 true HK1158563A1 (en) | 2012-07-20 |
Family
ID=41572470
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK11113251.4A HK1158563A1 (en) | 2008-08-19 | 2011-12-07 | Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions thereof, and methods of use |
Country Status (20)
Country | Link |
---|---|
US (4) | US8148414B2 (es) |
EP (2) | EP2334378B1 (es) |
JP (1) | JP5670331B2 (es) |
CN (1) | CN102123763B (es) |
AU (1) | AU2009282888C1 (es) |
CA (2) | CA2730478C (es) |
CY (1) | CY1115203T1 (es) |
DK (1) | DK2334378T3 (es) |
ES (1) | ES2477884T3 (es) |
HK (1) | HK1158563A1 (es) |
HR (1) | HRP20140640T1 (es) |
IL (2) | IL210579A (es) |
MX (1) | MX2011001341A (es) |
NZ (3) | NZ608196A (es) |
PL (1) | PL2334378T3 (es) |
PT (1) | PT2334378E (es) |
RU (1) | RU2554347C2 (es) |
SI (1) | SI2334378T1 (es) |
WO (1) | WO2010022177A2 (es) |
ZA (1) | ZA201100599B (es) |
Families Citing this family (119)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL1663197T3 (pl) | 2003-09-09 | 2008-09-30 | Biogen Idec Int Gmbh | Zastosowanie pochodnych kwasu fumarowego do leczenia niewydolności serca oraz astmy |
DE202005022112U1 (de) | 2004-10-08 | 2014-04-24 | Forward Pharma A/S | Pharmazeutische Zusammensetzungen mit kontrollierter Freisetzung, umfassend einen Fumarsaureester |
WO2008096271A2 (en) * | 2007-02-08 | 2008-08-14 | Ralf Gold | Neuroprotection in demyelinating diseases |
EP2334378B1 (en) | 2008-08-19 | 2014-04-09 | XenoPort, Inc. | Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions thereof, and methods of use |
RU2743637C2 (ru) | 2009-01-09 | 2021-02-20 | Фвп Ип Апс | Фармацевтический состав, содержащий один или более эфиров фумаровой кислоты в разлагаемой матрице |
PE20141316A1 (es) * | 2011-05-26 | 2014-10-01 | Biogen Idec Inc | Metodos para tratar la esclerosis multiple y preservar y/o aumentar el contenido de mielina |
WO2014037832A2 (en) | 2012-09-06 | 2014-03-13 | Mahesh Kandula | Compositions and methods for the treatment of epilepsy and neurological diseases |
US9504679B2 (en) | 2011-12-19 | 2016-11-29 | Bjoern Colin Kahrs | Pharmaceutical compositions comprising glitazones and Nrf2 activators |
US20130158077A1 (en) | 2011-12-19 | 2013-06-20 | Ares Trading S.A. | Pharmaceutical compositions |
NZ629728A (en) | 2012-02-07 | 2016-07-29 | Xenoport Inc | Morpholinoalkyl fumarate compounds, pharmaceutical compositions, and methods of use |
AU2013203445C1 (en) * | 2012-02-07 | 2017-04-20 | Biogen Ma Inc. | Pharmaceutical compositions containing dimethyl fumarate |
WO2013167990A1 (en) | 2012-05-07 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of depression |
JP2015519333A (ja) | 2012-05-07 | 2015-07-09 | セリックスビオ プライヴェート リミテッド | 神経疾患の治療のための組成物および方法 |
CN104603096A (zh) | 2012-05-07 | 2015-05-06 | 塞利克斯比奥私人有限公司 | 用于治疗神经肌肉障碍和神经退行性疾病的组合物和方法 |
US9403826B2 (en) | 2012-05-08 | 2016-08-02 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammatory disorders |
US9522884B2 (en) | 2012-05-08 | 2016-12-20 | Cellix Bio Private Limited | Compositions and methods for the treatment of metabolic disorders |
US9434704B2 (en) | 2012-05-08 | 2016-09-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological degenerative disorders |
US9266823B2 (en) | 2012-05-08 | 2016-02-23 | Cellix Bio Private Limited | Compositions and methods for the treatment of parkinson's disease |
US9309233B2 (en) | 2012-05-08 | 2016-04-12 | Cellix Bio Private Limited | Compositions and methods for the treatment of blood clotting disorders |
US9499526B2 (en) | 2012-05-10 | 2016-11-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurologic diseases |
US9346742B2 (en) | 2012-05-10 | 2016-05-24 | Cellix Bio Private Limited | Compositions and methods for the treatment of fibromyalgia pain |
WO2013168000A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of severe pain |
WO2013168002A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of neurological conditions |
US9242939B2 (en) | 2012-05-10 | 2016-01-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of respiratory disorders |
WO2013167999A2 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of neurologic diseases |
WO2013168011A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of chronic pain |
WO2013168015A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of asthma and allergy |
US9321775B2 (en) | 2012-05-10 | 2016-04-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of moderate to severe pain |
WO2013168005A2 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of restless leg syndrome and fibromyalgia |
US9499527B2 (en) | 2012-05-10 | 2016-11-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of familial amyloid polyneuropathy |
WO2013168016A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of metabolic syndrome |
WO2013167997A2 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of metabolic syndrome |
US9492409B2 (en) | 2012-05-23 | 2016-11-15 | Cellix Bio Private Limited | Compositions and methods for the treatment of local pain |
WO2013175377A2 (en) | 2012-05-23 | 2013-11-28 | Mahesh Kandula | Compositions and methods for the treatment of mucositis |
AU2013264896A1 (en) | 2012-05-23 | 2014-11-27 | Cellixbio Private Limited | Compositions and methods for the treatment of multiple sclerosis |
WO2013175357A2 (en) | 2012-05-23 | 2013-11-28 | Mahesh Kandula | Compositions and methods for the treatment of inflammatory bowel disease |
US9434729B2 (en) | 2012-05-23 | 2016-09-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of periodontitis and rheumatoid arthritis |
WO2013175347A2 (en) | 2012-05-23 | 2013-11-28 | Mahesh Kandula | Compositions and methods for the treatment of respiratory disorders |
EP2854795A1 (en) * | 2012-05-30 | 2015-04-08 | XenoPort, Inc. | Treatment of multiple sclerosis and psoriasis using prodrugs of methyl hydrogen fumarate |
US9108942B1 (en) | 2014-11-05 | 2015-08-18 | Mahesh Kandula | Compositions and methods for the treatment of moderate to severe pain |
WO2014020480A2 (en) | 2012-08-03 | 2014-02-06 | Mahesh Kandula | Compositions and methods for the treatment migraine and neurologic diseases |
US20140057918A1 (en) * | 2012-08-22 | 2014-02-27 | Xenoport, Inc. | Methods of Use for Monomethyl Fumarate and Prodrugs Thereof |
EP2887933A1 (en) * | 2012-08-22 | 2015-07-01 | XenoPort, Inc. | Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof |
CA2882713A1 (en) * | 2012-08-22 | 2014-02-27 | Xenoport, Inc. | Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects |
US20200000758A1 (en) * | 2012-08-22 | 2020-01-02 | Xenoport, Inc. | Oral Dosage Forms Of Methyl Hydrogen Fumarate And Prodrugs Thereof |
WO2014037833A2 (en) | 2012-09-06 | 2014-03-13 | Mahesh Kandula | Compositions and methods for the treatment inflammation and lipid disorders |
EP2892878A4 (en) | 2012-09-08 | 2016-02-24 | Cellix Bio Private Ltd | COMPOSITIONS AND METHODS FOR TREATING INFLAMMATION AND LIPID DISORDER |
US20150157590A9 (en) | 2012-11-05 | 2015-06-11 | Xenoport, Inc. | Cocrystals of (n,n-diethylcarbamoyl)methyl methyl (2e)but-2-ene-1,4-dioate |
EP2742855A1 (en) * | 2012-12-11 | 2014-06-18 | Friedrich-Alexander-Universität Erlangen-Nürnberg | Brain functional magnetic resonance activity is associated with response to tumor necrosis factor inhibition |
US20140171504A1 (en) | 2012-12-14 | 2014-06-19 | Georgia Regents Research Institute, Inc. | Methods of Treating Sickle Cell Disease and Related Disorders Using Fumaric Acid Esters |
WO2014096425A2 (en) * | 2012-12-21 | 2014-06-26 | Ratiopharm Gmbh | Prodrugs of monomethyl fumarate (mmf) |
ES2733961T3 (es) * | 2012-12-21 | 2019-12-03 | Biogen Ma Inc | Derivados de fumarato sustituidos con deuterio |
US8669281B1 (en) | 2013-03-14 | 2014-03-11 | Alkermes Pharma Ireland Limited | Prodrugs of fumarates and their use in treating various diseases |
RS57497B1 (sr) | 2013-03-14 | 2018-10-31 | Alkermes Pharma Ireland Ltd | Prolekovi fumarata i njihova upotreba u lečenju raznih bolesti |
US20140275250A1 (en) * | 2013-03-15 | 2014-09-18 | Xenoport, Inc. | Methods of Administering Monomethyl Fumarate |
WO2014160633A1 (en) | 2013-03-24 | 2014-10-02 | Xenoport, Inc. | Pharmaceutical compositions of dimethyl fumarate |
US9333187B1 (en) | 2013-05-15 | 2016-05-10 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammatory bowel disease |
WO2014195961A1 (en) | 2013-06-04 | 2014-12-11 | Mahesh Kandula | Compositions and methods for the treatment of diabetes and pre-diabetes |
US9302977B2 (en) | 2013-06-07 | 2016-04-05 | Xenoport, Inc. | Method of making monomethyl fumarate |
WO2014205392A1 (en) * | 2013-06-21 | 2014-12-24 | Xenoport, Inc. | Cocrystals of dimethyl fumarate |
EP3027767A1 (en) * | 2013-08-01 | 2016-06-08 | XenoPort, Inc. | Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects |
WO2015017798A2 (en) * | 2013-08-02 | 2015-02-05 | CRIXlabs, Inc. | Method and system for predicting spatial and temporal distributions of therapeutic substance carriers |
EP3041467A1 (en) | 2013-09-06 | 2016-07-13 | XenoPort, Inc. | Crystalline forms of (n,n-diethylcarbamoyl)methyl methyl (2e)but-2-ene-1,4-dioate, methods of synthesis and use |
WO2015043688A1 (en) * | 2013-09-27 | 2015-04-02 | Ratiopharm Gmbh | Prodrugs of monomethyl fumarate (mmf) |
ES2686721T3 (es) * | 2013-12-05 | 2018-10-19 | Ratiopharm Gmbh | Derivados de ácido tartárico |
US9096537B1 (en) | 2014-12-31 | 2015-08-04 | Mahesh Kandula | Compositions and methods for the treatment of mucositis |
AU2015218587B2 (en) | 2014-02-24 | 2017-04-27 | Alkermes Pharma Ireland Limited | Sulfonamide and sulfinamide prodrugs of fumarates and their use in treating various diseases |
WO2015128488A1 (en) * | 2014-02-27 | 2015-09-03 | Ratiopharm Gmbh | Derivatives of polyhydroxy compounds |
US9636318B2 (en) | 2015-08-31 | 2017-05-02 | Banner Life Sciences Llc | Fumarate ester dosage forms |
US9326965B2 (en) | 2014-02-28 | 2016-05-03 | Banner Life Sciences Llc | Controlled release fumarate esters |
US9326947B1 (en) | 2014-02-28 | 2016-05-03 | Banner Life Sciences Llc | Controlled release fumarate esters |
US10098863B2 (en) | 2014-02-28 | 2018-10-16 | Banner Life Sciences Llc | Fumarate esters |
US9999672B2 (en) | 2014-03-24 | 2018-06-19 | Xenoport, Inc. | Pharmaceutical compositions of fumaric acid esters |
PL3131633T3 (pl) * | 2014-04-17 | 2020-08-24 | Wolfgang Albrecht | Pochodne MMF etylenoglikoli |
WO2015172083A1 (en) | 2014-05-08 | 2015-11-12 | Biogen Ma Inc. | Dimethylfumarate and prodrugs for treatment of multiple sclerosis |
JP6735729B2 (ja) | 2014-08-04 | 2020-08-05 | ライジェル ファーマシューティカルズ, インコーポレイテッド | フマレート類似体および自己免疫疾患または炎症性疾患の治療におけるその使用 |
WO2016046835A1 (en) | 2014-09-26 | 2016-03-31 | Cellix Bio Private Limited | Compositions and methods for the treatment of epilepsy and neurological disorders |
AU2014407862B2 (en) | 2014-09-29 | 2020-03-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of multiple sclerosis |
WO2016061393A1 (en) | 2014-10-15 | 2016-04-21 | Xenoport, Inc. | Fumarate compounds, pharmaceutical compositions, and methods of use |
CN107108535B (zh) | 2014-10-27 | 2020-04-28 | 塞尔利克斯生物私人有限公司 | 用于治疗多发性硬化的富马酸单甲酯与哌嗪或乙二胺的三组分盐 |
US9321716B1 (en) | 2014-11-05 | 2016-04-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of metabolic syndrome |
US9173877B1 (en) | 2014-11-05 | 2015-11-03 | Cellix Bio Private Limited | Compositions and methods for the treatment of local pain |
US9175008B1 (en) | 2014-11-05 | 2015-11-03 | Cellix Bio Private Limited | Prodrugs of anti-platelet agents |
US9150557B1 (en) | 2014-11-05 | 2015-10-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of hyperglycemia |
US10208014B2 (en) | 2014-11-05 | 2019-02-19 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological disorders |
US9290486B1 (en) | 2014-11-05 | 2016-03-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of epilepsy |
US9284287B1 (en) | 2014-11-05 | 2016-03-15 | Cellix Bio Private Limited | Compositions and methods for the suppression of carbonic anhydrase activity |
MA40985A (fr) | 2014-11-17 | 2017-09-26 | Biogen Ma Inc | Méthodes de traitement de la sclérose en plaques |
JP2017537088A (ja) * | 2014-12-01 | 2017-12-14 | セリックス バイオ プライヴェート リミテッドCellix Bio Private Limited | 多発性硬化症の治療のための組成物及び方法 |
US9932294B2 (en) | 2014-12-01 | 2018-04-03 | Cellix Bio Private Limited | Compositions and methods for the treatment of multiple sclerosis |
MA41139A (fr) | 2014-12-11 | 2017-10-17 | Actelion Pharmaceuticals Ltd | Combinaison pharmaceutique comportant un agoniste sélectif du récepteur sip1 |
US9206111B1 (en) | 2014-12-17 | 2015-12-08 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological diseases |
EP3242869B1 (en) | 2015-01-06 | 2021-10-27 | Cellixbio Private Limited | Compositions and methods for the treatment of inflammation and pain |
US9409872B1 (en) * | 2015-02-16 | 2016-08-09 | Mark Quang Nguyen | Fumarate compounds, pharmaceutical compositions thereof, and methods of use |
MA41785A (fr) | 2015-03-20 | 2018-01-23 | Biogen Ma Inc | Procédés et compositions pour l'administration intraveineuse de fumarates pour le traitement de maladies neurologiques |
JP6487752B2 (ja) * | 2015-03-31 | 2019-03-20 | 大阪瓦斯株式会社 | ジカルボン酸又はエステル及びそれを用いた樹脂並びにそれらの製造方法 |
US9598354B2 (en) * | 2015-05-03 | 2017-03-21 | Mark Quang Nguyen | Fumarate compounds, pharmaceutical compositions thereof, and methods of use |
WO2016182898A1 (en) * | 2015-05-08 | 2016-11-17 | Xenoport, Inc. | Methods of use for monomethyl fumarate and prodrugs thereof |
US10213411B2 (en) | 2015-08-27 | 2019-02-26 | Vijaykumar Rajasekhar | Use of prodrugs of fumarates in treating heart failure diseases |
WO2017108960A1 (en) * | 2015-12-22 | 2017-06-29 | Ratiopharm Gmbh | Method for producing monomethyl fumarate compounds |
US10463642B2 (en) | 2016-02-01 | 2019-11-05 | Vijaykumar Rajasekhar | Methods of treating heart failure diseases using prodrugs of methyl hydrogen fumarate |
MX2019005568A (es) * | 2016-11-11 | 2019-09-27 | Cellix Bio Private Ltd | Composiciones y metodos para el tratamiento de polipos gastrointestinales. |
WO2018162625A1 (en) | 2017-03-09 | 2018-09-13 | Truly Translational Sweden Ab | Prodrugs of sulfasalazine, pharmaceutical compositions thereof and their use in the treatment of autoimmune disease |
US11370748B2 (en) | 2017-09-05 | 2022-06-28 | 1Globe Biomedical Co., Ltd. | Therapeutics for central nervous system disorders |
AU2018352362B2 (en) * | 2017-10-16 | 2024-02-01 | Dynamic Biologics Inc. | Polymeric compositions of monomethyl fumarate in treating relapsing–remitting multiple sclerosis and psoriasis |
CN108358852B (zh) * | 2018-01-25 | 2021-07-20 | 于磊 | Sglt2蛋白的抑制剂以及应用 |
WO2020094767A1 (en) | 2018-11-08 | 2020-05-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of nrf2 activators for the treatment of staphylococcus aureus infections |
SG11202105525YA (en) * | 2018-12-06 | 2021-06-29 | Flagship Pioneering Innovations V Inc | Monomethyl fumarate-carrier conjugates and methods of their use |
KR102675526B1 (ko) | 2019-01-30 | 2024-06-14 | (주)애거슨바이오 | 모노메틸 푸마레이트 전구체 약물 화합물 및 이들의 약학적 조성물 |
KR20200101200A (ko) | 2019-02-19 | 2020-08-27 | 틴트리바이오 (주) | 모노메틸 푸마레이트 유도체 및 이들의 약학적 조성물 |
JP7406566B2 (ja) * | 2019-04-17 | 2023-12-27 | イクシェル ファーマ エルエルシー | フマル酸モノメチルのプロドラッグ |
WO2021142062A1 (en) | 2020-01-10 | 2021-07-15 | Banner Life Sciences Llc | Fumarate ester dosage forms with enhanced gastrointestinal tolerability |
MX2022010962A (es) | 2020-03-06 | 2022-10-07 | Actelion Pharmaceuticals Ltd | Metodos para ralentizar la perdida de volumen cerebral. |
CN115298159A (zh) * | 2020-03-13 | 2022-11-04 | 阿德莱德大学 | 与氧化应激相关的病症的治疗和用于其的化合物 |
WO2022038365A2 (en) * | 2020-08-21 | 2022-02-24 | Sitryx Therapeutics Limited | Novel compounds |
EP4415699A1 (en) | 2021-10-11 | 2024-08-21 | Laboratoires Juvise Pharmaceuticals | Methods of treating multiple sclerosis |
WO2023152290A1 (en) | 2022-02-11 | 2023-08-17 | Actelion Pharmaceuticals Ltd | Methods of slowing an increase in brain ventricular volume |
WO2024047248A1 (en) | 2022-09-02 | 2024-03-07 | Institut National de la Santé et de la Recherche Médicale | Use of nrf2 activators for the treatment of cerebral small vessel disease |
CN116307280B (zh) * | 2023-05-18 | 2023-08-01 | 成都理工大学 | 一种酸性气藏气井储层硫堵损伤量化评估方法 |
Family Cites Families (113)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3139395A (en) | 1961-01-09 | 1964-06-30 | American Cyanamid Co | Photodimerization of fumaric acid derivatives |
DE1165586B (de) | 1961-07-13 | 1964-03-19 | Dr Walter Schliesser | Verfahren zur Herstellung von Fumarsaeuremonoalkylestern durch Isomerisieren von Maleinsaeurehalbestern |
US3336364A (en) | 1964-05-19 | 1967-08-15 | Monsanto Co | Di(allyloxymethyl)butyl bis esters |
GB1153927A (en) | 1966-08-25 | 1969-06-04 | Wilhelm Hoerrmann | Medicinal Composition Suitable For Treating Diseases Of The Retina |
DE2163060A1 (de) | 1971-12-18 | 1973-06-20 | Basf Ag | Waesserige dispersionen von mischpolymerisaten von monoestern olefinisch ungesaettigter dicarbonsaeuren |
JPS60181047U (ja) | 1984-05-10 | 1985-12-02 | 九州日本電気株式会社 | リ−ドフレ−ム |
CH664150A5 (de) | 1985-01-15 | 1988-02-15 | Peter Paul Prof Dr Speiser | Fumarsaeureprodrug, verfahren zu seiner herstellung und dieses enthaltende darreichungsformen. |
US5149695A (en) | 1985-01-15 | 1992-09-22 | Speiser Peter P | Fumaric acid derivatives, process for the production thereof and pharmaceutical compositions containing same |
DE3617626A1 (de) | 1986-05-26 | 1987-12-03 | Bayer Ag | Substituierte 6-hydroxymethyl-carbapenem-antibiotika, verfahren zu ihrer herstellung und ihre verwendung |
DK406686D0 (da) | 1986-08-26 | 1986-08-26 | Hans Bundgaard | Carboxylsyrederivater |
US4959389A (en) | 1987-10-19 | 1990-09-25 | Speiser Peter P | Pharmaceutical preparation for the treatment of psoriatic arthritis |
US5424332A (en) | 1987-10-19 | 1995-06-13 | Speiser; Peter P. | Pharmaceutical composition and process for the production thereof |
PL153592B1 (pl) | 1988-07-08 | 1991-05-31 | Politechnika Wroclawska | SPOSÓB OTRZYMYWANIA NOWEGO 2-/2'-ffYDROKSY-3'-/l"-KARBONYLOKSY-2"- KARBOBUTOKSY-E-ETENO/ACBTAMIDOMETYLO-5 *-METYLOFENYLO/-2H-BENZOTRlAZOLU-1, 2,3 |
JP2850471B2 (ja) | 1990-04-11 | 1999-01-27 | 日本油脂株式会社 | 不飽和ジカルボン酸モノエステルの製造方法 |
PH31064A (en) | 1990-09-07 | 1998-02-05 | Nycomed As Of Nycoveten | Polymers containing diester units. |
JP2964607B2 (ja) * | 1990-10-11 | 1999-10-18 | 日産自動車株式会社 | 油圧供給装置 |
US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
US5932214A (en) | 1994-08-11 | 1999-08-03 | Biogen, Inc. | Treatment for inflammatory bowel disease with VLA-4 blockers |
CH681891A5 (es) | 1992-10-09 | 1993-06-15 | Marigen Sa | |
GB9411115D0 (en) | 1994-06-03 | 1994-07-27 | Secr Defence | Stabilisation of photosensitive material |
WO1996036613A1 (fr) | 1995-05-19 | 1996-11-21 | Nippon Soda Co., Ltd. | Derives d'acides benzoiques substitues, procede de production desdits derives et herbicides |
US6130248A (en) | 1996-12-30 | 2000-10-10 | Bar-Ilan University | Tricarboxylic acid-containing oxyalkyl esters and uses thereof |
AU5617398A (en) * | 1996-12-30 | 1998-07-31 | Beacon Laboratories L.L.C. | Tricarboxylic acid-containing oxyalkyl esters and uses thereof |
DE19721099C2 (de) | 1997-05-20 | 1999-12-02 | Fumapharm Ag Muri | Verwendung von Fumarsäurederivaten |
SE9702000D0 (sv) | 1997-05-28 | 1997-05-28 | Astra Ab | New pharmaceutical formulation |
DE19814358C2 (de) | 1998-03-31 | 2002-01-17 | Fumapharm Ag Muri | Verwendung von Alkylhydrogenfumaraten zur Behandlung von Psoriasis, psoriatischer Arthritis, Neurodermitis und Enteritis regionalis Crohn |
US6126949A (en) | 1998-04-06 | 2000-10-03 | Bernel Chemical Company, Inc. | Di-behenyl fumarate and its use in dermatological products |
AU4261699A (en) | 1998-05-29 | 1999-12-20 | Infineum Usa Lp | Wax crystal modifiers formed from dialkyl phenyl fumarate |
ES2228078T3 (es) | 1998-08-18 | 2005-04-01 | Takara Bio Inc. | Remedios o preventivos que contienen compuestos de ciclopentenona como ingrediente activo. |
DE19839566C2 (de) | 1998-08-31 | 2002-01-17 | Fumapharm Ag Muri | Verwendung von Fumarsäurederivaten in der Transplantationsmedizin |
DE19848260C2 (de) | 1998-10-20 | 2002-01-17 | Fumapharm Ag Muri | Fumarsäure-Mikrotabletten |
DE19853487A1 (de) | 1998-11-19 | 2000-05-25 | Fumapharm Ag Muri | Verwendung von Dialkylfumaraten |
JP2001158760A (ja) | 1999-12-01 | 2001-06-12 | Nisso Yuka Kogyo Kk | フマル酸モノアルキルエステルおよびそのナトリウム塩の製造法 |
SE9904850D0 (sv) | 1999-12-30 | 1999-12-30 | Pharmacia & Upjohn Ab | Novel process and intermediates |
DE10000577A1 (de) * | 2000-01-10 | 2001-07-26 | Fumapharm Ag Muri | Verwendung von Fumarsäurederivaten zur Behandlung mitochondrialer Krankheiten |
EP1130112A1 (en) | 2000-02-24 | 2001-09-05 | Epidauros Biotechnologie AG | Method for detecting the presence of at least one single allele of a deletion mutant |
PL392750A1 (pl) * | 2001-01-12 | 2011-05-23 | Fumapharm Ag | Amidy kwasu fumarowego |
DE10101307A1 (de) | 2001-01-12 | 2002-08-01 | Fumapharm Ag Muri | Fumarsäurederivate als NF-kappaB-Inhibitor |
US20030114527A1 (en) | 2001-08-31 | 2003-06-19 | Karnachi Anees Abdulquadar | Pharmaceutical composition |
US6613800B1 (en) | 2001-12-03 | 2003-09-02 | Steven A. Smith | Method and compositions for treating psoriasis, eczema, seborrhea and arthritis |
AU2003211560A1 (en) | 2002-02-20 | 2003-09-09 | Ajinomoto Co., Inc. | Novel phenylalanine derivative |
DE10217314A1 (de) | 2002-04-18 | 2003-11-13 | Fumapharm Ag Muri | Carbocyclische und Oxacarboncyclische Fumarsäure-Oligomere |
US6709868B2 (en) | 2002-05-20 | 2004-03-23 | Portascience Inc. | Method and apparatus for measuring white blood cell count |
US20040102525A1 (en) | 2002-05-22 | 2004-05-27 | Kozachuk Walter E. | Compositions and methods of treating neurological disease and providing neuroprotection |
US7959914B2 (en) | 2003-05-16 | 2011-06-14 | Acorda Therapeutics, Inc. | Methods of reducing extravasation of inflammatory cells |
GB0320441D0 (en) | 2003-09-02 | 2003-10-01 | Givaudan Sa | Organic compounds |
DE10360869A1 (de) | 2003-09-09 | 2005-04-07 | Fumapharm Ag | Verwendung von Fumarsäurederivaten zur Therapie der Herzinsuffizienz, der Hyperkeratose und von Asthma |
PL1663197T3 (pl) | 2003-09-09 | 2008-09-30 | Biogen Idec Int Gmbh | Zastosowanie pochodnych kwasu fumarowego do leczenia niewydolności serca oraz astmy |
DE10342423A1 (de) | 2003-09-13 | 2005-04-14 | Heidland, August, Prof. Dr.med. Dr.h.c. | Verwendung von Fumarsäurederivaten zur Prophylaxe und zur Behandlung von Genomschäden |
WO2005044262A1 (en) | 2003-10-29 | 2005-05-19 | Wyeth | Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof |
US20050096369A1 (en) | 2003-11-04 | 2005-05-05 | Hoang Ba X. | Compositions and methods for treating cellular proliferation disorders |
CN100537513C (zh) | 2004-09-23 | 2009-09-09 | 李文佳 | 反丁烯二酸单甲酯的制备工艺 |
DE202005022112U1 (de) | 2004-10-08 | 2014-04-24 | Forward Pharma A/S | Pharmazeutische Zusammensetzungen mit kontrollierter Freisetzung, umfassend einen Fumarsaureester |
TWI279403B (en) | 2004-10-20 | 2007-04-21 | Eternal Chemical Co Ltd | Cyclobutanetetracarboxylate compound and preparation method thereof |
US20080004344A1 (en) | 2004-11-10 | 2008-01-03 | Aditech Pharma Ab | Novel Salts of Fumaric Acid Monoalkylesters and Their Pharmaceutical Use |
WO2006050730A1 (en) | 2004-11-10 | 2006-05-18 | Aditech Pharma Ab | Novel salts of fumaric acid monoalkylesters and their pharmaceutical use |
DE102005022845A1 (de) | 2005-05-18 | 2006-11-23 | Fumapharm Ag | Thiobernsteinsäurederivate und deren Verwendung |
US20060269925A1 (en) | 2005-05-25 | 2006-11-30 | The General Hospital Corporation | Methods for determining glutathione S-transferase theta-1 genotype |
WO2007006307A2 (en) | 2005-07-07 | 2007-01-18 | Aditech Pharma Ab | Novel salts of fumaric acid monoalkylesters and their pharmaceutical use |
DE602006011910D1 (de) | 2005-07-07 | 2010-03-11 | Aditech Pharma Ag | Neue glucopyranoseester und glucofuranoseester von fumarsäurealkylestern und deren pharmazeutische verwendung |
EP1940382A2 (en) | 2005-10-07 | 2008-07-09 | Aditech Pharma AB | Combination therapy with fumaric acid esters for the treatment of autoimmune and/or inflammatory disorders |
WO2007042034A1 (en) | 2005-10-07 | 2007-04-19 | Aditech Pharma Ab | Controlled release pharmaceutical compositions comprising a fumaric acid ester |
WO2007103839A2 (en) * | 2006-03-07 | 2007-09-13 | Bristol-Myers Squibb Company | Pyrrolotriazine aniline prodrug compounds useful as kinase inhibitors |
EP2019671B1 (en) | 2006-05-05 | 2014-09-24 | The Regents Of The University Of Michigan | Intermediates for the preparation of bivalent smac mimetics |
US20080089861A1 (en) | 2006-07-10 | 2008-04-17 | Went Gregory T | Combination therapy for treatment of demyelinating conditions |
WO2008096271A2 (en) | 2007-02-08 | 2008-08-14 | Ralf Gold | Neuroprotection in demyelinating diseases |
EP4137819A1 (en) | 2007-02-08 | 2023-02-22 | Biogen MA Inc. | Compositions and uses for treating multiple sclerosis |
EP1985697A1 (en) | 2007-04-27 | 2008-10-29 | AM-Pharma B.V. | Modified phosphatases |
CN101888851B (zh) | 2007-08-21 | 2013-11-20 | 美国中西部大学 | 使用内皮缩血管肽b受体激动剂治疗中风或脑血管意外的组合物 |
CN101318901A (zh) | 2008-06-17 | 2008-12-10 | 健雄职业技术学院 | 一种富马酸二甲酯的合成新工艺 |
US20140193386A1 (en) | 2008-06-18 | 2014-07-10 | Lifebond Ltd. | Method for enzymatic cross-linking of a protein |
EP2334378B1 (en) * | 2008-08-19 | 2014-04-09 | XenoPort, Inc. | Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions thereof, and methods of use |
CA2740017A1 (en) | 2008-10-20 | 2010-04-29 | Xenoport, Inc. | Methods of synthesizing a levodopa ester prodrug |
WO2010048389A2 (en) | 2008-10-23 | 2010-04-29 | Henkel Corporation | Pharmaceutical pellets comprising modified starch and therapeutic applications therefor |
KR20100052262A (ko) | 2008-11-10 | 2010-05-19 | (주)아모레퍼시픽 | 난용성 약물의 나노입자를 포함하는 분말의 제조방법, 그에의해 제조된 분말 및 이를 포함하는 약학적 조성물 |
US20120034274A1 (en) | 2009-01-09 | 2012-02-09 | Forward Pharma A/S | Pharmaceutical composition comprising one or more fumaric acid esters |
RU2743637C2 (ru) | 2009-01-09 | 2021-02-20 | Фвп Ип Апс | Фармацевтический состав, содержащий один или более эфиров фумаровой кислоты в разлагаемой матрице |
KR20110126747A (ko) | 2009-03-06 | 2011-11-23 | 제노포트 인코포레이티드 | 고용량의 가바펜틴 프로드러그를 갖는 경구 투여 제형 |
US20100260755A1 (en) | 2009-04-09 | 2010-10-14 | Medicinova, Inc. | Ibudilast and immunomodulators combination |
CA2760133A1 (en) | 2009-04-29 | 2010-11-04 | Biogen Idec Ma Inc. | Treatment of neurodegeneration and neuroinflammation |
EP2343075A1 (en) | 2010-01-04 | 2011-07-13 | Neurotec Pharma, S.L. | Diazoxide for use in the treatment a central nervous system (CNS) autoimmune demyelinating disease |
CN101774913B (zh) | 2010-01-08 | 2013-05-29 | 河南大学 | 一种富马酸单甲酯的制备方法 |
SG182414A1 (en) | 2010-01-08 | 2012-08-30 | Catabasis Pharmaceuticals Inc | Fatty acid fumarate derivatives and their uses |
PE20141316A1 (es) | 2011-05-26 | 2014-10-01 | Biogen Idec Inc | Metodos para tratar la esclerosis multiple y preservar y/o aumentar el contenido de mielina |
RS56972B1 (sr) | 2011-06-08 | 2018-05-31 | Biogen Ma Inc | Postupak za pripremu visoko-čistog i kristalnog dimetil fumarata |
US20140308244A1 (en) | 2011-08-08 | 2014-10-16 | The Board Of Trustees Of The Leland Stanford Junior University | Combination Therapy for Treatment of Inflammatory Demyelinating Disease |
DK2751279T3 (da) | 2011-08-31 | 2017-11-20 | St Jude Children's Res Hospital | Fremgangsmåder og sammensætninger til påvisning af niveauet af lysosomal exocytose-aktivitet og fremgangsmåder til anvendelse |
WO2013076216A1 (en) | 2011-11-24 | 2013-05-30 | Synthon Bv | Controlled release particles comprising dimethyl fumarate |
WO2013090799A1 (en) | 2011-12-16 | 2013-06-20 | Biogen Idec Ma Inc. | Silicon-containing fumaric acid esters |
US20130158077A1 (en) | 2011-12-19 | 2013-06-20 | Ares Trading S.A. | Pharmaceutical compositions |
NZ629728A (en) | 2012-02-07 | 2016-07-29 | Xenoport Inc | Morpholinoalkyl fumarate compounds, pharmaceutical compositions, and methods of use |
AU2013203445C1 (en) | 2012-02-07 | 2017-04-20 | Biogen Ma Inc. | Pharmaceutical compositions containing dimethyl fumarate |
KR20230066482A (ko) | 2012-03-07 | 2023-05-15 | 아미쿠스 세라퓨틱스, 인코포레이티드 | 폼페병의 치료를 위한 고농도 알파-글루코시다제 조성물 |
US20130259856A1 (en) | 2012-03-27 | 2013-10-03 | Teva Pharmaceutical Industries, Ltd. | Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate |
EP2854795A1 (en) | 2012-05-30 | 2015-04-08 | XenoPort, Inc. | Treatment of multiple sclerosis and psoriasis using prodrugs of methyl hydrogen fumarate |
EP2692343A1 (en) | 2012-08-03 | 2014-02-05 | Forward Pharma A/S | Combination therapy for treatment of multiple sclerosis |
EP2887933A1 (en) | 2012-08-22 | 2015-07-01 | XenoPort, Inc. | Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof |
US20140057918A1 (en) | 2012-08-22 | 2014-02-27 | Xenoport, Inc. | Methods of Use for Monomethyl Fumarate and Prodrugs Thereof |
CA2882713A1 (en) | 2012-08-22 | 2014-02-27 | Xenoport, Inc. | Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects |
US20150157590A9 (en) | 2012-11-05 | 2015-06-11 | Xenoport, Inc. | Cocrystals of (n,n-diethylcarbamoyl)methyl methyl (2e)but-2-ene-1,4-dioate |
WO2014096425A2 (en) | 2012-12-21 | 2014-06-26 | Ratiopharm Gmbh | Prodrugs of monomethyl fumarate (mmf) |
ES2733961T3 (es) | 2012-12-21 | 2019-12-03 | Biogen Ma Inc | Derivados de fumarato sustituidos con deuterio |
US8669281B1 (en) | 2013-03-14 | 2014-03-11 | Alkermes Pharma Ireland Limited | Prodrugs of fumarates and their use in treating various diseases |
RS57497B1 (sr) | 2013-03-14 | 2018-10-31 | Alkermes Pharma Ireland Ltd | Prolekovi fumarata i njihova upotreba u lečenju raznih bolesti |
US20140275250A1 (en) | 2013-03-15 | 2014-09-18 | Xenoport, Inc. | Methods of Administering Monomethyl Fumarate |
WO2014160633A1 (en) | 2013-03-24 | 2014-10-02 | Xenoport, Inc. | Pharmaceutical compositions of dimethyl fumarate |
WO2014190056A2 (en) | 2013-05-21 | 2014-11-27 | Biogen Idec Ma Inc. | Prodrugs and drugs |
US9302977B2 (en) | 2013-06-07 | 2016-04-05 | Xenoport, Inc. | Method of making monomethyl fumarate |
WO2014205392A1 (en) | 2013-06-21 | 2014-12-24 | Xenoport, Inc. | Cocrystals of dimethyl fumarate |
EP3027767A1 (en) | 2013-08-01 | 2016-06-08 | XenoPort, Inc. | Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects |
EA201690102A1 (ru) | 2013-08-26 | 2016-06-30 | Форвард Фарма А/С | Фармацевтическая композиция, содержащая диметилфумарат, для введения в низкой суточной дозе |
EP3041467A1 (en) | 2013-09-06 | 2016-07-13 | XenoPort, Inc. | Crystalline forms of (n,n-diethylcarbamoyl)methyl methyl (2e)but-2-ene-1,4-dioate, methods of synthesis and use |
WO2015042294A1 (en) | 2013-09-18 | 2015-03-26 | Xenoport, Inc. | Nanoparticle compositions of dimethyl fumarate |
-
2009
- 2009-08-19 EP EP09791679.5A patent/EP2334378B1/en not_active Not-in-force
- 2009-08-19 ES ES09791679.5T patent/ES2477884T3/es active Active
- 2009-08-19 AU AU2009282888A patent/AU2009282888C1/en not_active Ceased
- 2009-08-19 EP EP13176359.1A patent/EP2650279A3/en not_active Withdrawn
- 2009-08-19 MX MX2011001341A patent/MX2011001341A/es active IP Right Grant
- 2009-08-19 CN CN200980132350.0A patent/CN102123763B/zh not_active Expired - Fee Related
- 2009-08-19 NZ NZ608196A patent/NZ608196A/en not_active IP Right Cessation
- 2009-08-19 NZ NZ590746A patent/NZ590746A/xx not_active IP Right Cessation
- 2009-08-19 JP JP2011523968A patent/JP5670331B2/ja not_active Expired - Fee Related
- 2009-08-19 RU RU2011110435/04A patent/RU2554347C2/ru not_active IP Right Cessation
- 2009-08-19 PL PL09791679T patent/PL2334378T3/pl unknown
- 2009-08-19 NZ NZ602496A patent/NZ602496A/xx not_active IP Right Cessation
- 2009-08-19 US US12/544,133 patent/US8148414B2/en active Active
- 2009-08-19 PT PT97916795T patent/PT2334378E/pt unknown
- 2009-08-19 WO PCT/US2009/054349 patent/WO2010022177A2/en active Application Filing
- 2009-08-19 CA CA2730478A patent/CA2730478C/en not_active Expired - Fee Related
- 2009-08-19 DK DK09791679.5T patent/DK2334378T3/da active
- 2009-08-19 CA CA2806444A patent/CA2806444C/en not_active Expired - Fee Related
- 2009-08-19 SI SI200930954T patent/SI2334378T1/sl unknown
-
2011
- 2011-01-11 IL IL210579A patent/IL210579A/en not_active IP Right Cessation
- 2011-01-24 ZA ZA2011/00599A patent/ZA201100599B/en unknown
- 2011-10-14 US US13/274,284 patent/US8785443B2/en active Active
- 2011-10-14 US US13/274,282 patent/US8778991B2/en active Active
- 2011-12-07 HK HK11113251.4A patent/HK1158563A1/xx not_active IP Right Cessation
-
2014
- 2014-06-06 US US14/298,668 patent/US9452972B2/en active Active
- 2014-06-27 CY CY20141100474T patent/CY1115203T1/el unknown
- 2014-07-07 HR HRP20140640AT patent/HRP20140640T1/hr unknown
-
2015
- 2015-04-16 IL IL238327A patent/IL238327A0/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL238327A0 (en) | Fumaric acid monomethyl ester prodrugs, pharmaceutical compositions containing them and methods of use | |
IL271132A (en) | New preparation and dosage | |
IL245172A0 (en) | Pharmaceutical preparations and methods for transferring them related to them | |
HK1194071A1 (en) | Certain triazolopyrazines, compositions thereof and methods of use therefor | |
HK1160728A1 (en) | Stable insecticide compositions and methods for producing same | |
HK1145803A1 (en) | Devices, formulations, and methods for delivery of multiple beneficial agents | |
IL206288A0 (en) | Novel dosage and formulation | |
IL210843A0 (en) | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
IL218212A0 (en) | Therapeutic methods and compositions | |
IL210097B (en) | Compounds and methods for the treatment of influenza | |
ZA201004030B (en) | Pharmaceutical compositions for treating depression and anxiety | |
EP2152232A4 (en) | METHOD AND COMPOSITIONS FOR OXYBUTYNINE ADMINISTRATION | |
HK1148956A1 (en) | Imidazopyridazines as par1 inhibitors, production thereof, and use thereof as medicaments | |
HK1149011A1 (en) | Triazolopyridazines as par1 inhibitors, production thereof, and use for producing medicaments | |
EP2461870A4 (en) | THERAPEUTIC COMPOSITIONS AND METHOD | |
EP2300044A4 (en) | METHOD AND COMPOSITIONS FOR TREATING PAIN WITH OMEGA CONOTOXINES | |
SG10201405262SA (en) | Pharmaceutical compositions for treating depression and anxiety |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20180822 |